Overview

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Summary

Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension

Phase:

Phase 3

Details

Lead Sponsor:

Novartis